Public US private equity stocks have seen valuations climb over the past year, buoyed by successful pivots towards private credit deals and optimism around increasing M&A activity as we emerge from a challenging dealmaking environment.
Bourne continues to be one of the most active Pharma Services Advisors, having closed 7 transactions with 7 different sponsors within the last 45 days with more to come! Select recent clients and counterparties include:
